Stereotactic body radiation therapy in pancreatic cancer: The new frontier

Shalini Moningi, Ariel E. Marciscano, Lauren M. Rosati, Sook Kien Ng, Roland Teboh Forbang, Juan Jackson, Daniel T. Chang, Albert C. Koong, Joseph M. Herman

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Pancreatic cancer (PCA) remains a disease with a poor prognosis. The majority of PCA patients are unable to undergo surgical resection, which is the only potentially curative option at this time. A combination of chemotherapy and chemoradiation (CRT) are standard options for patients with locally advanced, unresectable disease, however, local control and patient outcomes remains poor. Stereotactic body radiation therapy (SBRT) is an emerging treatment option for PCA. SBRT delivers potentially ablative doses to the pancreatic tumor plus a small margin over a short period of time. Early studies with single-fraction SBRT demonstrated excellent tumor control with high rates of toxicity. The implementation of SBRT (3-5 doses) has demonstrated promising outcomes with favorable tumor control and toxicity rates. Herein we discuss the evolving role of SBRT in PCA treatment.

Original languageEnglish (US)
Pages (from-to)1461-1475
Number of pages15
JournalExpert Review of Anticancer Therapy
Issue number12
StatePublished - Dec 1 2014


  • locally advanced
  • pancreatic cancer
  • radiation oncology
  • radiation therapy
  • stereotactic body radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Stereotactic body radiation therapy in pancreatic cancer: The new frontier'. Together they form a unique fingerprint.

Cite this